본문
L&C Bio (KOSDAQ: 290650) announced on the 13th that its clinical research paper on MegaCarti® has been published in the Orthopaedic Journal of Sports Medicine (OJSM), an SCI-grade academic journal with an impact factor (I.F) of 2.6.
OJSM is the official journal of the American Orthopaedic Society for Sports Medicine (AOSSM), founded in 1972, and is now in its 51st year.
The title of the published study is:
“Particulated Costal Allocartilage With Microfracture Versus Microfracture Alone for Knee Cartilage Defects: A Multicenter, Prospective, Randomized, Participant- and Rater-Blinded Study.”
Authors of the paper include Professors Seong-Hwan Kim, Hyung-Jun Kim, and Joon-Nam Beom from Gangnam Severance Hospital, Professor Min Jeong from Severance Hospital, Professor Kwang-Ho Jung from Yongin Severance Hospital, Professor Ki-Mo Jang from Anam Hospital, and Professor Sang-Hoon Park from NHIS Ilsan Hospital.
The clinical study targeted 90 patients diagnosed with ICRS Grade 3–4 (an international standard for severe cartilage defects). Patients were randomly assigned to one of two groups: the treatment group, which received MegaCarti® after microfracture surgery, and the control group, which received microfracture alone.
At 48 weeks, the treatment group showed a significantly improved MOCART score (Magnetic Resonance Observation of Cartilage Repair Tissue) of 56.0 ± 10.5, compared to 43.0 ± 17.4 in the control group.
Clinical evaluations at 12, 24, and 48 weeks—based on VAS (Visual Analog Scale) and KOOS (Knee injury and Osteoarthritis Outcome Score)—also showed statistically significant improvements in the MegaCarti® group compared to the control.
The study concluded that the combination of MegaCarti® and microfracture not only demonstrated safety but also superior cartilage regeneration and functional improvement.
CEO Hwan-Chul Lee of L&C Bio stated,
“This marks the 58th publication for L&C Bio, and it’s a meaningful milestone. As a company that has grown through research-driven, evidence-based marketing, we will continue to support R&D to sustain our mission and philosophy.”
